Larimar Therapeutics, Inc. rose 11.9% on Friday, November 13, 2026, on 2,531,399 shares. No headline about LRMR came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Larimar Therapeutics, Inc. (LRMR:NASDAQ) closed at $3.02 on November 13, 2026, up 11.85% on the day. The stock trades 53.0% below its 52-week high of $6.42 and 57.7% above its 52-week low of $1.92. Over the past year, it lost 10.7%. Larimar Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, LRMR closed higher on 116 days (46%). Its best day was February 25, 2026 (+61.25%) and its worst was November 5, 2026 (-15.94%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 3 times.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Find more stocks like LRMR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.